

Robert T Keenan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3516655/publications.pdf>

Version: 2024-02-01

37
papers

1,211
citations

471509

17
h-index

377865

34
g-index

38
all docs

38
docs citations

38
times ranked

1432
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Anti-Interleukin-6 Antibodies for Autoimmune Retinopathy with Macular Edema. <i>Ophthalmology Retina</i> , 2022, 6, 91-93. | 2.4 | 3 |
| 2 | Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response. <i>Current Rheumatology Reports</i> , 2022, 24, 12-19. | 4.7 | 4 |
| 3 | Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.. <i>Clinical and Experimental Rheumatology</i> , 2022, , . | 0.8 | 0 |
| 4 | The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 347-352. | 3.4 | 26 |
| 5 | A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. <i>Arthritis and Rheumatology</i> , 2021, 73, 1533-1542. | 5.6 | 45 |
| 6 | RECONSTITUTION OF THE ELLIPSOID ZONE WITH TOCILIZUMAB IN AUTOIMMUNE RETINOPATHY. <i>Retinal Cases and Brief Reports</i> , 2020, 14, 297-300. | 0.6 | 7 |
| 7 | The biology of urate. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, S2-S10. | 3.4 | 82 |
| 8 | Colorectal Cancer Among Gout Patients Undergoing Colonoscopy. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 335-340. | 0.9 | 4 |
| 9 | Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434. | 3.4 | 73 |
| 10 | Is It Time for Gout Flare Treatment to Move into the 21st Century?. <i>Journal of Rheumatology</i> , 2019, 46, 667-669. | 2.0 | 1 |
| 11 | Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600. | 0.9 | 72 |
| 12 | Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase. <i>Rheumatology and Therapy</i> , 2019, 6, 299-304. | 2.3 | 17 |
| 13 | Moving the Needle: Improving the Care of the Gout Patient. <i>Rheumatology and Therapy</i> , 2019, 6, 179-193. | 2.3 | 14 |
| 14 | SARILUMAB FOR RECALCITRANT CYSTOID MACULAR EDEMA IN NON-PARANEOPLASTIC AUTOIMMUNE RETINOPATHY. <i>Retinal Cases and Brief Reports</i> , 2019, Publish Ahead of Print, 504-508. | 0.6 | 10 |
| 15 | Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2018, 7, e009328. | 3.7 | 32 |
| 16 | The role of cystoid macular edema as a marker in the progression of non-paraneoplastic autoimmune retinopathy. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 1867-1873. | 1.9 | 11 |
| 17 | Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review. <i>Clinical Therapeutics</i> , 2017, 39, 430-441. | 2.5 | 34 |
| 18 | An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. <i>American Heart Journal</i> , 2017, 187, 53-61. | 2.7 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 811-820. | 0.9 | 141 |
| 20 | Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking. <i>Clinical Rheumatology</i> , 2017, 36, 2101-2107. | 2.2 | 26 |
| 21 | Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 754-758. | 3.4 | 26 |
| 22 | Etiology and Pathogenesis of Hyperuricemia and Gout. , 2017, , 1597-1619.e6. | | 4 |
| 23 | New and Pipeline Drugs for Gout. <i>Current Rheumatology Reports</i> , 2016, 18, 32. | 4.7 | 15 |
| 24 | Current and Emerging Therapies for Gout. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 143-155. | 1.4 | 4 |
| 25 | CaseBook Challenges: Managing Gout, Hyperuricemia and Comorbiditiesâ€”Dialogue with the Experts. <i>American Journal of Medicine</i> , 2014, 127, S1. | 1.5 | 3 |
| 26 | Inpatient Gout: A Review. <i>Current Rheumatology Reports</i> , 2014, 16, 458. | 4.7 | 4 |
| 27 | Genetics of Hyperuricemia and Gout: Implications for the Present and Future. <i>Current Rheumatology Reports</i> , 2013, 15, 309. | 4.7 | 31 |
| 28 | Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with Gout. <i>Journal of Rheumatology</i> , 2012, 39, 1458-1464. | 2.0 | 173 |
| 29 | Safety of Urate-Lowering Therapies. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 663-680. | 1.9 | 16 |
| 30 | Prevalence of Contraindications and Prescription of Pharmacologic Therapies for Gout. <i>American Journal of Medicine</i> , 2011, 124, 155-163. | 1.5 | 168 |
| 31 | Gout, Hyperuricemia, and the Risk of Cardiovascular Disease: Cause and Effect?. <i>Current Rheumatology Reports</i> , 2010, 12, 118-124. | 4.7 | 45 |
| 32 | Gout and its comorbidities. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2010, 68, 199-203. | 0.7 | 42 |
| 33 | RS3PE Presenting in a Unilateral Pattern: Case Report and Review of the Literature. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 38, 428-433. | 3.4 | 23 |
| 34 | Hyperuricemia, gout, and cardiovascular disease--an important "muddle". <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2009, 67, 285-90. | 0.7 | 8 |
| 35 | Febuxostat: A new agent for lowering serum urate. <i>Drugs of Today</i> , 2009, 45, 247. | 1.1 | 4 |
| 36 | Update on the management of hyperuricemia and gout. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2008, 66, 231-9. | 0.7 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels. <i>Clinical and Experimental Rheumatology</i> , 0, , . | 0.8 | 0 |